Treosulfan-based conditioning regimens for allogeneic haematopoietic stem cell transplantation in children with non-malignant diseases

Bone Marrow Transplantation

Volumn 50, Issue 12, 2015, Pages 1536-1541

  Slatter, M A ^a   Boztug, H ^b   Potschger U ^b   Sykora, K W ^c   Lankester, A ^d   Yaniv, I ^e   Sedlacek, P ^f   Glogova, E ^b   Veys, P ^g   Gennery, A R ^a   Peters, C ^b  

^a Newcastle Upon Tyne Hospitals NHS Foundation Trust   (United Kingdom)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e TEL AVIV UNIVERSITY   (Israel)

^f UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^g GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; TREOSULFAN; BUSULFAN;

ADOLESCENT; AGE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOIMMUNE DISEASE; BONE MARROW DEPRESSION; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; CONTROLLED STUDY; DIARRHEA; EVENT FREE SURVIVAL; FEMALE; GENETIC DISORDER; GRAFT VERSUS HOST REACTION; HEMOGLOBINOPATHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; RETROSPECTIVE STUDY; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; VOMITING; ALLOGRAFT; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DISEASE FREE SURVIVAL; INFANT; MULTICENTER STUDY; PRESCHOOL CHILD; PROCEDURES; RISK FACTOR; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING;

ADOLESCENT; AGE FACTORS; ALLOGRAFTS; BUSULFAN; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFANT; MALE; RETROSPECTIVE STUDIES; RISK FACTORS; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION CONDITIONING;

EID: 84949102772     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2015.171     Document Type: Article

References (25)

1. Sjoo F, Hassan Z, Abedi-Valugerdi M, Griskevicius L, Nilsson C, Remberger M et al. Myeloablative and immunosuppressive properties of treosulfan in mice. Exp Hematol 2006; 34: 115-121
2. Ten Brink MH, Zwaveling J, Swen JJ, Bredius RG, Lankester AC, Guchelaar HJ. Personalized busulfan and treosulfan conditioning for pediatric stem cell transplantation: the role of pharmacogenetics and pharmacokinetics. Drug Discov Today 2014; 19: 1572-1586
3. Beelen DW, Trenschel R, Casper J, Freund M, Hilger RA, Scheulen ME et al. Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications. Bone Marrow Transplant 2005; 35: 233-241
4. Casper J, Knauf W, Kiefer T, Wolff D, Steiner B, Hammer U et al. Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. Blood 2004; 103: 725-731
5. Slatter MA, Rao K, Amrolia P, Flood T, Abinun M, Hambleton S et al. Treosulfan-based conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency (PID): UK experience. Blood 2011; 117: 4367-4375
6. Greystoke B, Bonanomi S, Carr TF, Gharib M, Khalid T, Coussons M et al. Treosulfan-containing regimens achieve high rates of engraftment associated with low transplant morbidity and mortality in children with non-malignant disease and significant co-morbidities. Br J Haematol 2008; 142: 257-262
7. Glowka FK, Romanski M, Wachowiak J. High-dose treosulfan in conditioning prior to hematopoietic stem cell transplantation. Expert Opin Investig Drugs 2010; 19: 1275-1295
8. Beier R, Schulz A, Honig M, Eyrich M, Schlegel PG, Holter W et al. Long-term follow-up of children conditioned with Treosulfan: German and Austrian experience. Bone Marrow Transplant 2013; 48: 491-501
9. Lehmberg K, Albert MH, Beier R, Beutel K, Gruhn B, Kroger N et al. Treosulfanbased conditioning regimen for children and adolescents with hemophagocytic lymphohistiocytosis. Haematologica 2014; 99: 180-184
10. Cutting R, Mirelman A, Vora A. Treosulphan as an alternative to busulphan for myeloablative conditioning in paediatric allogeneic transplantation. Br J Haematol 2008; 143: 748-751
11. Boztug H, Zecca M, Sykora KW, Veys P, Lankester A, Slatter M et al. Treosulfanbased conditioning regimens for allogeneic HSCT in children with acute lymphoblastic leukaemia. Ann Hematol 2014; 94: 297-306
12. Burroughs LM, Nemecek ER, Torgerson TR, Storer BE, Talano JA, Domm J et al. Treosulfan-based conditioning and hematopoietic cell transplantation for nonmalignant diseases: a prospective multicenter trial. Biol Blood Marrow Transplant 2014; 20: 1996-2003
13. Nemecek ER, Guthrie KA, Sorror ML, Wood BL, Doney KC, Hilger RA et al. Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies. Biol Blood Marrow Transplant 2011; 17: 341-350
14. Mathews V, George B, Viswabandya A, Abraham A, Ahmed R, Ganapule A et al. Improved clinical outcomes of high risk beta thalassemia major patients undergoing a HLA matched related allogeneic stem cell transplant with a treosulfan based conditioning regimen and peripheral blood stem cell grafts. PLoS One 2013; 8: e61637
15. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304
16. Klein JP, Rizzo JD, Zhang MJ, Keiding N. Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part I: unadjusted analysis. Bone Marrow Transplant 2001; 28: 909-915
17. Klein JP, Rizzo JD, Zhang MJ, Keiding N. Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part 2: Regression modeling. Bone Marrow Transplant 2001; 28: 1001-1011
18. Fine JG, Gray R. J. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496-509
19. Gray RJ. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141-1154
20. Choudhary D, Sharma SK, Gupta N, Kharya G, Pavecha P, Handoo A et al. Treosulfan-thiotepa-fludarabine-based conditioning regimen for allogeneic transplantation in patients with thalassemia major: a single-center experience from north India. Biol Blood Marrow Transplant 2013; 19: 492-495
21. Bernardo ME, Piras E, Vacca A, Giorgiani G, Zecca M, Bertaina A et al. Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan. Blood 2012; 120: 473-476
22. Gennery AR, Slatter MA, Grandin L, Taupin P, Cant AJ, Veys P et al. Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better? J Allergy Clin Immunol 2010; 126: 602-610.e1-11
23. Romanski M, Tezyk A, Zaba C, Glowka FK. Rapid and sensitive liquid chromatography-tandem mass spectrometry method for determination of protein-free pro-drug treosulfan and its biologically active monoepoxytransformer in plasma and brain tissue. Talanta 2014; 127: 123-132
24. Ten Brink MH, Ackaert O, Zwaveling J, Bredius RG, Smiers FJ, den Hartigh J et al. Pharmacokinetics of treosulfan in pediatric patients undergoing hematopoietic stem cell transplantation. Ther Drug Monit 2014; 36: 465-472
25. Gungor T, Teira P, Slatter M, Stussi G, Stepensky P, Moshous D et al. Reducedintensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. Lancet 2014; 383: 436-448